Previous studies reported that an FcγRIIIa polymorphism at position 158 is associated with the therapeutic efficacy of tumor-targeting mAbs [44–46], and we previously reported that this polymorphism was found in patients predisposed to infectious complications following liver transplantation [20]. This evidence concerns the gene FCGR3A and neoplasm.